Scribe Therapeutics Inc. SCTX
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -60.84% | -86.96% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -60.84% | -86.96% | |||
| Cost of Revenue | -36.45% | -29.30% | |||
| Gross Profit | 23.16% | -900.00% | |||
| SG&A Expenses | -5.72% | -49.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -31.54% | -35.37% | |||
| Operating Income | 19.20% | -123.63% | |||
| Income Before Tax | 40.98% | -357.73% | |||
| Income Tax Expenses | 129.78% | 172.38% | |||
| Earnings from Continuing Operations | 34.60% | -406.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 34.60% | -406.48% | |||
| EBIT | 19.20% | -123.63% | |||
| EBITDA | 19.75% | -145.29% | |||
| EPS Basic | 35.83% | -397.59% | |||
| Normalized Basic EPS | 19.68% | -141.36% | |||
| EPS Diluted | 35.83% | -397.59% | |||
| Normalized Diluted EPS | 19.68% | -141.36% | |||
| Average Basic Shares Outstanding | 1.93% | 1.79% | |||
| Average Diluted Shares Outstanding | 1.93% | 1.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||